Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Social Media
Republican Party
Natural Disasters
Drones
US Politics
Donald Trump
Money
Senate
Democratic Party
Gold
Instagram
Published • loading... • Updated

PARAMUNE Trial: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer

Summary by Baylor College of Medicine
S2303 PARAMMUNE: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Baylor College of MedicineBaylor College of Medicine

PARAMUNE Trial: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer

S2303 PARAMMUNE: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Baylor College of Medicine broke the news in on Wednesday, May 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Houston, Texas

Houston, Texas

News
For You
SearchBlindspotLocal